Practicing urologists as a whole must stay close to the cutting edge of laparoscopic renal surgery.
In 2006, there seem to be few new hurdles to climb in laparoscopic extirpative renal surgery or, for that matter, even laparoscopic reconstructive procedures. These high standards do come at a price, as learning curve complications are often unavoidable, regardless of the skill or experience of the surgeons. There is no denying the global trend toward laparoscopic and minimally invasive renal surgery and the rapid acceptance of laparoscopic partial nephrectomy at many larger metropolitan centers.
Two articles in this issue of Urology Times focus on important aspects of laparoscopic partial nephrectomy.
This report offers technical caveats along with extensive results and complications, all of which provide invaluable insight. The importance of strong skills in laparoscopic suturing and the use of biologic hemostatic agents are most notable, in my opinion.
Osamu Ukimura, MD, and associates, also from the Cleveland Clinic, reported on a subset of laparoscopic partial nephrectomy patients, those with pT2 and pT3 tumors. In this study, a nonblinded radiologist could not predict the presence of tumor invasion in the perirenal fat using CT scan. The researchers conclude that excision of the overlying perirenal fat be performed in higher-risk lesions. Certainly, this report speaks to the importance of maintaining sound oncologic principles when performing laparoscopic oncology.
In the end, the real winners should be our patients, who rightly seek optimal cancer treatment with minimal morbidity. And while select centers of excellence have led the way for urologists worldwide in renal laparoscopy, practicing urologists as a whole must stay close to the cutting edge of laparoscopic renal surgery in order to ensure urology's dominance in the management of renal tumors.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.